Schizophrenia News and Research

Latest Schizophrenia News and Research

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

2 Feb 2012

Study finds no link between BDV and psychiatric illness

Over the past 30 years, numerous studies have linked Borna disease virus (BDV) with mental illnesses such as bipolar disorder, schizophrenia, anxiety disorder and dementia. Genetic fragments and antibodies to this RNA virus, which causes behavior disorders in a range of mammals and birds, have been found to be prevalent in psychiatric patients, but study results have been inconsistent. Now, the first blinded, case-control study to examine this issue finds no association between the virus and psychiatric illness.

1 Feb 2012

States redesigning mental health programs, coverage and care

States are grappling with mental health issues including a redesign of a program in Iowa, increased coverage for the mentally ill in California and a mental health first aid pilot program in Pennsylvania.

30 Jan 2012

Genetic variation predisposes children to complications linked with second-generation anti-psychotics

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease.

25 Jan 2012

Changes in endocannabinoid system may have important implications for psychiatric disorders

Changes in the endocannabinoid system may have important implications for psychiatric and addiction disorders. This brain system is responsible for making substances that have effects on brain function which resemble those of cannabis products, e.g., marijuana.

25 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Inmates with severe mental illnesses alone have lower rates of recidivism

People with mental illness have gotten a bad rap in past research studies, being labeled the group of people with the highest return rates to prison. But a researcher from the Mandel School of Applied Social Sciences at Case Western Reserve University counters those findings in a new study-demonstrating that inmates with severe mental illnesses alone actually have lower rates of recidivism than those with substance abuse issues or no mental or substance abuse issues.

18 Jan 2012

Teenagers more susceptible to addiction and depression

Teenagers are more susceptible to developing disorders like addiction and depression, according to a paper published by Pitt researchers Jan. 16 in the Proceedings of the National Academy of Sciences.

18 Jan 2012

Weight gain and other metabolic side effects of bipolar and schizophrenia drugs may be countered

A new study suggests that young people who are diagnosed with bipolar disorder and schizophrenia may be spared the side-effects of taking medication with the right diet and exercise program.

11 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Scientists map neurons that process different kinds of visual information

There's a 3-D world in our brains. It's a landscape that mimics the outside world, where the objects we see exist as collections of neural circuits and electrical impulses.

7 Jan 2012

Study: Younger the age at migration, higher the risk of psychotic disorders

Recent research has found striking links between psychotic disorders such as schizophrenia and certain types of international immigration. Now for the first time, a major study has found that immigrating in early childhood appears to carry the highest risk.

6 Jan 2012

Oxytocin can make rhesus macaques pay more attention to each other

Oxytocin, the "love hormone" that builds mother-baby bonds and may help us feel more connected toward one another, can also make surly monkeys treat each other a little more kindly.

6 Jan 2012

RGS9-2 gene plays a role in regulating body weight

Abraham Kovoor was studying a brain protein, called RGS9 2, that he had previously related to the involuntary, random and repetitive body movements that are side effects of drugs used to treat Parkinson's disease and schizophrenia.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Lundbeck announces availability of ONFI Tablets in the U.S.

Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

4 Jan 2012

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

BioLineRx, a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040), a novel medical device intended for the prevention of cardiac remodeling following an acute myocardial infarction (AMI).

4 Jan 2012

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

Schizophrenia News and Research

Latest Schizophrenia News and Research

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

Study finds no link between BDV and psychiatric illness

States redesigning mental health programs, coverage and care

Genetic variation predisposes children to complications linked with second-generation anti-psychotics

Changes in endocannabinoid system may have important implications for psychiatric disorders

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

SSRI use raises risk of fall among elderly with dementia: Study

Inmates with severe mental illnesses alone have lower rates of recidivism

Teenagers more susceptible to addiction and depression

Weight gain and other metabolic side effects of bipolar and schizophrenia drugs may be countered

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Scientists map neurons that process different kinds of visual information

Study: Younger the age at migration, higher the risk of psychotic disorders

Oxytocin can make rhesus macaques pay more attention to each other

RGS9-2 gene plays a role in regulating body weight

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Lundbeck announces availability of ONFI Tablets in the U.S.

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Forensics and toxicology - Industry Focus eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Schizophrenia News and Research

Latest Schizophrenia News and Research

Forensics and toxicology - Industry Focus eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in